---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-453730"
form_type: "8-K/A"
ticker: "ZYME"
cik: "0001937653"
company_name: "Zymeworks Inc."
filed_at: "2026-11-09T21:39:21+00:00"
generated_at: "2026-11-09T21:40:09.791028+00:00"
event_type: "m_and_a"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Zymeworks completes Theravance merger; pro forma 9M26 net income $11.8M on $321.2M revenue

## Summary
- Merger completed Sept 23, 2026: each Theravance share converted into $17.00 cash plus one CVR tied to ampreloxetine proceeds and sales.
- Consideration for shares $887.2M plus $28.4M equity awards; total $915.6M, reduced by $355.2M cash acquired, net $560.4M.
- Financing includes $350M OMERS non-recourse notes at 8.25%, maturing Dec 31, 2036, secured by YUPELRI assets with 75% of YUPELRI profit-share cash flows assigned.
- Pro forma 9M 2026 revenue $321.2M and net income $11.8M ($0.15 diluted EPS); FY2025 pro forma revenue $213.4M and net loss $43.7M ($0.58).
- Preliminary purchase accounting: $415.4M YUPELRI product rights, $96.7M TRELEGY milestone receivable, $104.4M goodwill, $91.6M unrecognized tax benefits.

## SEC filing metadata
- accession: 0001193125-26-453730
- form_type: 8-K/A
- ticker: ZYME
- cik: 0001937653
- company_name: Zymeworks Inc.
- filed_at: 2026-11-09T21:39:21+00:00
- event_type: m_and_a
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1937653/000119312526453730/0001193125-26-453730-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1937653/000119312526453730/d79244d8ka.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-453730
- JSON: https://secwatch.observer/filing/0001193125-26-453730.json
- Plain text: https://secwatch.observer/filing/0001193125-26-453730.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.